Hexa Reports Industry Onychomycosis (Tinea Unguium) Market | страница 2

The Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide also reviews of key players involved in
therapeutic development for Onychomycosis (Tinea Unguium) and features dormant and discontinued
projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the
molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical, Discovery and Unknown
stages are 1, 2, 6, 3, 3 and 1 respectively.
Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide helps in identifying and tracking emerging
players in the market and their portfolios, enhances decision making capabilities and helps to create effective
counter strategies to gain competitive advantage. The guide is built using data and information sourced from
proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university sites and industry-specific third party
sources. Additionally, various dynamic tracking processes ensure that the most recent developments are
captured on a real time basis.
Request A Sample copy of This Report @ http://www.hexareports.com/report/onychomycosis-
tinea-unguium-pipeline-review-h2-2017/request-sample
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and
relevance of data.
Scope
 The pipeline guide provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea
Unguium) (Infectious Disease).
 The pipeline guide reviews pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious
Disease) by companies and universities/research institutes based on information derived from
company and industry-specific sources.
 The pipeline guide covers pipeline products based on several stages of development ranging from pre-
registration till discovery and undisclosed stages.
 The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product
description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental
activities.
 The pipeline guide reviews key companies involved in Onychomycosis (Tinea Unguium) (Infectious
Disease) therapeutics and enlists all their major and minor projects.
 The pipeline guide evaluates Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics based
on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
 The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
Follow Us: